185 related articles for article (PubMed ID: 38607050)
1. Spotlight on New Hallmarks of Drug-Resistance towards Personalized Care for Epithelial Ovarian Cancer.
Frezzini S; Lonardi S
Cells; 2024 Mar; 13(7):. PubMed ID: 38607050
[TBL] [Abstract][Full Text] [Related]
2. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
3. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
[TBL] [Abstract][Full Text] [Related]
4. The Molecular Landscape Influencing Prognoses of Epithelial Ovarian Cancer.
Liu CL; Yuan RH; Mao TL
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356623
[TBL] [Abstract][Full Text] [Related]
5. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
[TBL] [Abstract][Full Text] [Related]
6. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
7. CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicles carrying miR-6836 derived from resistant tumor cells transfer cisplatin resistance of epithelial ovarian cancer via DLG2-YAP1 signaling pathway.
Zou Y; Zhao Z; Wang J; Ma L; Liu Y; Sun L; Song Y
Int J Biol Sci; 2023; 19(10):3099-3114. PubMed ID: 37416779
[No Abstract] [Full Text] [Related]
9. Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer.
Zhang L; Nadeem L; Connor K; Xu G
Curr Cancer Drug Targets; 2016; 16(5):429-41. PubMed ID: 27040353
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Freimund AE; Beach JA; Christie EL; Bowtell DDL
Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
12. SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma.
Zhang PF; Wu J; Luo JH; Li KS; Wang F; Huang W; Wu Y; Gao SP; Zhang XM; Zhang PN
Aging (Albany NY); 2019 Oct; 11(19):8204-8216. PubMed ID: 31581131
[TBL] [Abstract][Full Text] [Related]
13. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
Luo Y; Gui R
J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
[TBL] [Abstract][Full Text] [Related]
14. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
[TBL] [Abstract][Full Text] [Related]
15. Adipocyte‑rich microenvironment promotes chemoresistance via upregulation of peroxisome proliferator‑activated receptor gamma/ABCG2 in epithelial ovarian cancer.
Chen S; Liu Z; Wu H; Wang B; Ouyang Y; Liu J; Zheng X; Zhang H; Li X; Feng X; Li Y; Shen Y; Zhang H; Xiao B; Yu C; Deng W
Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38426604
[TBL] [Abstract][Full Text] [Related]
16. NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer.
Zhu J; Wu G; Song L; Cao L; Tan Z; Tang M; Li Z; Shi D; Zhang S; Li J
EBioMedicine; 2019 May; 43():238-252. PubMed ID: 31047858
[TBL] [Abstract][Full Text] [Related]
17. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
18. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
Feng LY; Li L
J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
[TBL] [Abstract][Full Text] [Related]
19. The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
Wambecke A; Ahmad M; Lambert B; Joly F; Poulain L; Denoyelle C; Meryet-Figuiere M
Gynecol Oncol; 2020 Mar; 156(3):726-733. PubMed ID: 31883617
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review).
Yang L; Xie HJ; Li YY; Wang X; Liu XX; Mai J
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35211759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
